A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 192 participants.
Also called NCT02072096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 192 participants
- Sponsor
- Registry
-
NCT02072096 -
2013-001473-24
-
- Other papers using this trial's data
- Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Germany, Puerto Rico, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02072096. Randomized; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2016-11-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- Acronym
- IMPERIUM
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Acarbose
- Intervention (Drug)
- Linagliptin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Liraglutide
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Exenatide once weekly (QW)
- Intervention (Drug)
- Exenatide twice daily (BID)
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02072096- Content hash
a79cc58b4d3eb3c63997f2e0c62cc32d99144833bc5baab555195b8590ff39ef